CS-622 HCl is primarily investigated for its potential therapeutic applications, particularly in the field of oncology. It is being studied as a targeted therapy for certain types of cancers, where it may inhibit specific pathways involved in tumor growth and proliferation. Researchers are exploring its efficacy in preclinical and clinical trials to determine its role in cancer treatment regimens. Additionally, its mechanism of action suggests it could be used in combination with other anticancer agents to enhance therapeutic outcomes. The compound is also of interest in drug development for its potential to address drug-resistant cancers, offering a promising avenue for improving patient prognosis.